VistaGen Therapeutics (NASDAQ:VTGN) Shares Cross Below Fifty Day Moving Average – Here’s Why

Posted by George Bondi on Jun 6th, 2026

VistaGen Therapeutics, Inc. (NASDAQ:VTGN – Get Free Report) shares passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.60 and traded as low as $0.55. VistaGen Therapeutics shares last traded at $0.5756, with a volume of 292,642 shares traded.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Wall Street Zen downgraded shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings restated a “sell (e+)” rating on shares of VistaGen Therapeutics in a report on Wednesday. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, VistaGen Therapeutics has an average rating of “Reduce” and a consensus target price of $0.95.

Check Out Our Latest Stock Analysis on VistaGen Therapeutics

VistaGen Therapeutics Trading Down 5.5%

The stock’s fifty day simple moving average is $0.60 and its 200-day simple moving average is $1.20. The stock has a market capitalization of $21.55 million, a PE ratio of -0.29 and a beta of 0.31.

Hedge Funds Weigh In On VistaGen Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE increased its holdings in VistaGen Therapeutics by 1,068.0% in the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after buying an additional 19,331 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of VistaGen Therapeutics during the 1st quarter valued at approximately $25,000. Marshall Wace LLP purchased a new stake in shares of VistaGen Therapeutics in the second quarter worth approximately $69,000. Jane Street Group LLC purchased a new stake in shares of VistaGen Therapeutics in the second quarter worth approximately $190,000. Finally, AdvisorShares Investments LLC grew its position in VistaGen Therapeutics by 1.9% in the 3rd quarter. AdvisorShares Investments LLC now owns 206,998 shares of the company’s stock valued at $735,000 after acquiring an additional 3,884 shares during the last quarter. Institutional investors own 78.39% of the company’s stock.

About VistaGen Therapeutics

(Get Free Report)

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.